1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Discovery Grant is a one-year, $50,000 grant from the American Brain Tumor Association that funds high-risk, high-impact research with the potential to change current diagnostic or treatment models for brain tumors. Designed as seed funding for early-stage faculty-level researchers, the grant helps scientists develop new ideas and gather preliminary data needed to apply for larger grants.
The ABTA's Research Program supports both established and new investigators in advancing the causes, effects, diagnosis, and treatment of brain tumors. Letters of Intent were accepted through December 10, 2025, for the 2026 funding cycle.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Discovery Grants - American Brain Tumor Association | Learn More The ABTA’s Research Program supports both established and new scientists in discovering more about the causes, effects, diagnosis, and treatment of brain tumors. Discovery Grants are one-year, $50,000 grants for high risk, high impact research with the potential to change current diagnostic or treatment models.
Grants are intended to provide seed-funding for early-stage faculty-level researchers to develop their new ideas, and to get the preliminary data needed to apply for larger grants. The ABTA is accepting Letters of Intent through December 10, 2025.
Read the 2026 Request for Applications Your research can make a difference The ABTA funded a Discovery Grant for Michael Olin, PhD , in 2012 to study how glioblastomas suppress the immune system. During this study, he discovered an immunosuppressive protein that was upregulated in response to anti-tumor vaccines. Dr. Olin now has a way to block it, and has founded a drug company, OX2 Therapeutics, to produce the inhibitor.
He and his colleagues have tested the drug in a clinical trial for companion dogs. Development of the human inhibitor is now complete and a Phase I trial is ongoing for patients with high-grade brain tumors. Dr. Olin and his colleagues hope to extend the trial to other solid tumors in the near future.
According to the current listing, eligibility includes: Early-stage faculty-level researchers with projects focused on brain tumors. Little preliminary data is needed. Confirm the full requirements in the official notice before applying.
The current listing shows $50,000 for 1 year. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Discovery Grant is funded by American Brain Tumor Association. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
ARPA-H's HEARING program (ARPA-H-SOL-26-154) — Hearing Enhancement through ARtificially Intelligent NeurotechnoloGy — held its Proposers' Day on June 8, 2026 and set Solution Summary deadlines for June 29 with Full Proposals due August 14. Single prime awardee, multiple Other Transaction Agreements, three integrated technical areas spanning intracortical recording and stimulation devices, wearable dynamic sound modulators, and AI-based auditory read/write algorithms. The first phase runs 18 months; the full effort runs 4.5 years through first-in-human clinical studies. For neurotech teams that have spent a decade in cochlear-implant or visual-prosthesis space, this is the moment the federal government bet on auditory cortex over the cochlea.
Read articleA Nature poll finds three-quarters of American scientists are considering working abroad. ERC applications from U.S. researchers have tripled. France and the EU pledged €500 million to recruit them. Inside the brain drain reshaping global science — and what it means for grant strategy.
Read article